haloperidol has been researched along with 2019 Novel Coronavirus Disease in 10 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND Rhabdomyolysis is a condition in which intracellular components are released into the blood and urine." | 5.72 | A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19. ( Hirose, N; Inoue, J; Ishii, J; Koshioka, S; Kunishima, H; Kurata, T; Matsuura, M; Nagumo, F; Sada, Y; Samura, M; Takada, K; Tanikawa, K; Uchida, M, 2022) |
| " It is probably no accident that a sequence from the SARS-CoV-2 orf1b gene is found in the human NTNG1 gene, implicated in schizophrenia, and that haloperidol, used to treat schizophrenia, may also be a treatment for COVID-19." | 3.96 | SARS-CoV-2 ( Lehrer, S; Rheinstein, PH, 2020) |
| "BACKGROUND Rhabdomyolysis is a condition in which intracellular components are released into the blood and urine." | 1.72 | A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19. ( Hirose, N; Inoue, J; Ishii, J; Koshioka, S; Kunishima, H; Kurata, T; Matsuura, M; Nagumo, F; Sada, Y; Samura, M; Takada, K; Tanikawa, K; Uchida, M, 2022) |
| "The outbreak of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus continually led to infect a large population worldwide." | 1.56 | Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis. ( Kumar, V; Pandey, P; Prakash, A; Prasad, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 1 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 1 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 1 |
| Peng, S | 1 |
| Shi, Y | 1 |
| Zhang, Z | 1 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 1 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 1 |
| Huang, XP | 1 |
| Liu, Y | 1 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 1 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Takada, K | 1 |
| Sada, Y | 1 |
| Samura, M | 1 |
| Matsuura, M | 1 |
| Hirose, N | 1 |
| Kurata, T | 1 |
| Nagumo, F | 1 |
| Ishii, J | 1 |
| Koshioka, S | 1 |
| Uchida, M | 1 |
| Inoue, J | 1 |
| Tanikawa, K | 1 |
| Kunishima, H | 1 |
| Wang, C | 1 |
| Zhou, J | 1 |
| Zong, C | 1 |
| Kajani, R | 1 |
| Apramian, A | 1 |
| Vega, A | 1 |
| Ubhayakar, N | 1 |
| Xu, P | 1 |
| Liu, A | 1 |
| Lehrer, S | 1 |
| Rheinstein, PH | 1 |
| Pandey, P | 1 |
| Prasad, K | 1 |
| Prakash, A | 1 |
| Kumar, V | 1 |
| Jaworowski, S | 1 |
| Weiser, M | 1 |
| Gropp, C | 1 |
| Malka, M | 1 |
| Subramanyam, AA | 1 |
| Nachane, HB | 1 |
| Mahajan, NN | 1 |
| Shinde, S | 1 |
| D Mahale, S | 1 |
| Gajbhiye, RK | 1 |
| Totomoch-Serra, A | 1 |
| Ibarra-Miramon, CB | 1 |
| Manterola, C | 1 |
| Hoertel, N | 1 |
| Sánchez-Rico, M | 1 |
| Vernet, R | 1 |
| Jannot, AS | 1 |
| Neuraz, A | 1 |
| Blanco, C | 1 |
| Lemogne, C | 1 |
| Airagnes, G | 1 |
| Paris, N | 1 |
| Daniel, C | 1 |
| Gramfort, A | 1 |
| Lemaitre, G | 1 |
| Bernaux, M | 1 |
| Bellamine, A | 1 |
| Beeker, N | 1 |
| Limosin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
1 trial available for haloperidol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Observational study of haloperidol in hospitalized patients with COVID-19.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Antiviral Agents; COVID-19; Disease-Free Survival; Fe | 2021 |
9 other studies available for haloperidol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19.
Topics: Acute Kidney Injury; COVID-19; Haloperidol; Hematuria; Humans; Male; Middle Aged; Rhabdomyolysis | 2022 |
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.
Topics: Aged; Antipsychotic Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Haloperidol; H | 2020 |
Neuroleptic malignant syndrome in a COVID-19 patient.
Topics: Acute Kidney Injury; Antipsychotic Agents; Betacoronavirus; Bromocriptine; C-Reactive Protein; Coron | 2020 |
SARS-CoV-2
Topics: Animals; Antiviral Agents; Base Sequence; Betacoronavirus; Chromosomes, Human, Pair 1; Coronavirus I | 2020 |
Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis.
Topics: Binding Sites; Computer Simulation; Coronavirus Nucleocapsid Proteins; COVID-19; COVID-19 Drug Treat | 2020 |
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.
Topics: Adult; Antipsychotic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Delusions; Haloperid | 2020 |
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.
Topics: Antipsychotic Agents; Asymptomatic Infections; COVID-19; Delusions; Female; Hallucinations; Haloperi | 2020 |
Persistent Hiccups as Main COVID-19 Symptom.
Topics: Cholesterol; Clonazepam; Comorbidity; COVID-19; COVID-19 Drug Treatment; Haloperidol; Hernia, Umbili | 2021 |